Pharsight

Axsome Malta patents expiration

1. Sunosi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11753368 AXSOME MALTA Treatment of sleep-wake disorders
Jun, 2026

(2 years from now)

US11439597 AXSOME MALTA Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(13 years from now)

US11648232 AXSOME MALTA Methods and compositions for treating excessive sleepiness
Jun, 2038

(14 years from now)

US11865098 AXSOME MALTA Methods and compositions for treating excessive sleepiness
Jun, 2038

(14 years from now)

US11560354 AXSOME MALTA Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof
Mar, 2039

(14 years from now)

US11160779 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11839599 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11839598 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11850226 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11850227 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11850228 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11857528 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

US11771666 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US11793776 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US11779554 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US11872203 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US11872204 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US11771667 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 2023-06-18

Market Authorisation Date: 17 June, 2019

Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa); Treatment of excessive daytime sleepiness with a dosing regimen ...

Dosage: TABLET;ORAL

How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage

SUNOSI family patents

Family Patents